Drug Delivery Innovation Center INVITE. 5 October 2017

Transcription

1 Drug Delivery Innovation Center INVITE 5 October 2017

2 Drug DeliveryInnovation Center The Drug Delivery Innovation Center officially started on September 1st, Founding Tier 1 members of the open consortium are the companies Bayer AG, LB Bohle GmbH, Merck KGaA(all Germany) and UCB S.A.(Belgium), together with the university partners TU Dortmund and HHU Düsseldorf. The INVITE GmbH, which is located in the CHEMPARK Leverkusen, Germany, leads the consortium and builds the legal frame. We are looking forward to discuss the opportunities of the DDIC with new members Contact: INVITE GmbH, Dr. Armin Schweiger, CHEMPARK Geb. W32, Leverkusen, schweiger@invite-research.com INVITE October 2017 Page 2

3 Vision and Mission Through partnership and close collaboration between academia, industry and public stakeholders we will build a world-class Center of Excellence in Drug Delivery Innovation. Anchored in NRW the center builds on established research platforms at the universities of Düsseldorf and Dortmund as well as at INVITE. The DDIC will foster international, multi-disciplinary networks in the area of research. Science Advance pharmaceutical science and innovation in close collaboration multidisciplinary academic networks and pharmaceutical industry (along value-chain), with a focus on precompetitive research. Increase fundamental process understanding as the foundation of advanced process control, modelling and prediction. Education The center will establish a master of industrial pharmacy and a unique doctoral training program to develop a highly skilled talent base for industry and academia. Products & Innovation for Patients (better healthcare for patients) The center will accelerate patient-centric innovation enabling to the development of new technologies and advanced healthcare products and services. INVITE October 2017 Page 3

4 DDIC a consortium of academia and partners in industry A broad network of partners from within and outside NRW is the basis for successful research as well as education and talent development that meets the needs of the pharmaceutical sector. Multi-disciplinary research collaborations: network of universities / research institutes from different disciplines International research consortia (in the areas of interest): e.g. CMAC, RCPE, Pharmaceutical industry: pre-competitive basis research and proprietary applications Equipment Manufacturer: new technologies for manufacturing and testing Pharmaceutical Suppliers: excipient manufacturer, medical device industry (delivery technologies) INVITE October 2017 Page 4

5 DDIC innovative solutions for current challenges in pharmaceutical industry Modeling and Prediction Drug Delivery Technologies Process Engineering Future Technologies Rationale formulation design / pharmaceutical material science In-silico testing / prediction of biopharmaceutical properties Process modeling and simulation (DoE process optimization and scale-up) Oral, solid dosage form: overcoming low solubility / poor bioavailability Inhalation technologies (incl. medical devices) Ocular drug delivery (incl. medical devices) Advance formulations for biologics Drug Delivery for special patient groups (pediatrics & geriatrics) Down-scaling (equipment & processes) Continuous Processing Advanced Process Understanding (incl. Design Space and Process-analytical technologies (PAT)) Nano-medicine, Nano-technology 3D-printing Drug delivery for cell-based / gene therapy INVITE October 2017 Page 5

6 CurrentAcademic Partners HHU Düsseldorf: TU Dortmund: Prof. Dr. J. Breitkreutz Prof. Dr. Dr. h.c. P. Kleinebudde Prof. Dr. G. Schembecker Prof. Dr. G. Sadowski Prof. Dr. M. Thommes Univ. Greifswald: Prof. Dr. W. Weitschies * LMU München: Prof. Dr. G. Winter* *to be finally confirmed INVITE October 2017 Page 6

7 Research Clusters Research Cluster 1 Low solubility / poor bioavailability of oral drugs 2 Drug delivery forms for special patient groups/ personalized medicines 3 Continuous processing 4 Fundamental process understanding/pat/scalability 5 Models for predicting biopharmaceutical properties 6 Drug formulations for biomolecules (focus: mabs and ADCs) 7 Nanomedicines/ nanotechnologies INVITE October 2017 Page 7

8 INVITE provides the perfect platform for a fast and successful set-up of DDIC INVITE was founded in the year 2010 with financial support of the government of NRW as publicprivate-partnership between Bayerand the Technical University of Dortmund as research center for innovative production technologiesand is located in the CHEMPARK Leverkusen. The Heinrich Heine University Düsseldorf joined the company as additional shareholder to support research in pharmaceutical technology in August Since 2012 INVITE had significantly contributed to successfully prove the technical feasibility of modular, continuous productionof chemical and biological APIs and also to the final definition of new industry standards. This was possible by building and using a large network with academic and industrial partners. New fields of interest are Smart Robotics and the Drug Delivery Innovation Center (DDIC@INVITE). INVITE October 2017 Page 8

9 Two options to become a member within the DDIC consortium You are invited to join DDIC as a member in one of two ways. As a tier 1 member you will be able to directly impact the scientific direction of the DDIC and capture all benefits that this platform will offer. A tier 2 memberships still offers substantial benefits of being a member of a broad public-private network - however with partly restricted options. Tier 1-Member Tier 2-Member Scientific Board (Definition of research topics at DDIC) + (+)* Technical Committee + - (PhD program review, e.g. once a month) PhD mentoring (individual PhD within fee) + - Access to DDIC facility + + Free Technical licenses + - Access to talents (PhD, master) + + Tier 2 community / network - + Access to Public Funding projects and consortia + + * one representative of the Tier 2 companies INVITE October 2017 Page 9

10 Two options to become a partner within the DDIC consortium The following membership fees apply: Tier 1-Membership: Euro/a; fix for a 5-year term (this includes 1 FTE for proprietary research) Tier 2-Membership: Euro/a; fix for a 3-year term In addition to proprietary and joint, pre-competitive research, which is funded by these partnership fees, the DDIC and its partners will also work on publicly funded projects, which provide a significant additional source of joint research within the scope of the DDIC. INVITE October 2017 Page 10

11 The DDIC provides a range of benefits to its members Access to the Open-Innovation Platform at INVITE Unique network of partners along the pharmaceutical value chain Shape technology development in the area of drug delivery with partners in academia and industry in a pre-competitive environment Leverage infrastructure at DDIC and at the universities INVITE offers the capabilities and experience (e.g. f3-factory) to set-up and successfully run publicly funded projects. Partners of DDIC will have the opportunity to join the (international) consortia for these projects First-hand insights into all joint research projects (20-30 PhD and master programs in steady state envisioned), thus substantially increasing return on own research investment via technical committee. Option to run proprietary research projects as part of on-going PhD-studies or as separate PhDstudies Temporary staff exchange (to DDIC or from DDIC to company) for training and development of new capabilities. Access to talents (i.e. graduates of PhD and master programs) Free technical non-exclusive, world-wide license to IP developed at the DDIC INVITE October 2017 Page 11

12 Executive Summary The Drug Delivery Innovation Center (DDIC) is unique in NRW and Germany It builds on strong academic research and many industrial companies in the pharmaceutical sector and will expand to create an international, multi-disciplinary network in the area of Drug Delivery Innovation. The center aims to bridge basic research and industry applications, strengthen pharmaceutical education (master of industrial pharmacy and PhD-programs) and ultimately deliver patient-centric innovation for better healthcare. The location directly connected to INVITE and the CHEMPARK Leverkusen -provides the optimal infrastructure for research and can be easily reached by private and public transportation. The Center for Drug Delivery Innovation offers privileged memberships to a broad range of players in the pharmaceutical industry along the value chain. Contact: INVITE GmbH, Dr. Armin Schweiger, CHEMPARK Geb. W32, Leverkusen, schweiger@invite-research.com INVITE October 2017 Page 12

13 INVITE GmbH CHEMPARK Building W Leverkusen Germany Phone: Research Center Otto-Bayer-Straße Cologne Germany N 6 99 E INVITE October 2017 Page 13